000167435 001__ 167435
000167435 005__ 20240229133539.0
000167435 0247_ $$2doi$$a10.3390/biom11020230
000167435 0247_ $$2pmid$$apmid:33562838
000167435 037__ $$aDKFZ-2021-00339
000167435 041__ $$aeng
000167435 082__ $$a570
000167435 1001_ $$aRehm, Martin$$b0
000167435 245__ $$aRepeated Measurements of Cardiac Troponin T and N-Terminal Pro-B-Type Natriuretic Peptide to Assess Long-Term Mortality Risk in Subjects with Osteoarthritis.
000167435 260__ $$aBasel$$bMDPI$$c2021
000167435 3367_ $$2DRIVER$$aarticle
000167435 3367_ $$2DataCite$$aOutput Types/Journal article
000167435 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1614341128_13852
000167435 3367_ $$2BibTeX$$aARTICLE
000167435 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000167435 3367_ $$00$$2EndNote$$aJournal Article
000167435 520__ $$aOsteoarthritis (OA) is associated with higher cardiovascular mortality risk. High-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are well-characterized prognostic cardiac markers. We aimed to describe the changes in biomarkers measured one year apart in a cohort of 347 subjects with OA who underwent hip or knee replacement surgery in 1995/1996 and to analyze the prognostic value of repeated measurements for long-term mortality. During a median follow-up of 19 years, 209 (60.2%) subjects died. Substantial changes in cardiac biomarkers, especially for NT-proBNP, and an independent prognostic value of NT-proBNP for long-term mortality were found for both baseline measurement concentration (hazard ratio (HR) 1.32, 95% confidence interval (CI) (1.13-1.55)) and follow-up measurement concentration (HR 1.39, 95% CI 1.18-1.64) (all HR per standard deviation increase after natural log-transformation). Baseline concentrations were correlated with follow-up concentrations of NT-proBNP and no longer showed prognostic value when included simultaneously in a single model (HR 1.08, 95% CI 0.86-1.37), whereas the estimate for the one-year measurement remained robust (HR 1.31, 95% CI 1.04-1.66). Therefore, no significant additional benefit of repeated NT-proBNP measurements was found in this cohort, facilitating the use of a single NT-proBNP measurement as a stable prognostic marker.
000167435 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000167435 588__ $$aDataset connected to CrossRef, PubMed,
000167435 650_7 $$2Other$$aN-terminal pro-B-type natriuretic peptide (NT-proBNP)
000167435 650_7 $$2Other$$acohort study
000167435 650_7 $$2Other$$ahigh-sensitivity cardiac troponin T (hs-cTnT)
000167435 650_7 $$2Other$$amortality
000167435 650_7 $$2Other$$aosteoarthritis
000167435 650_7 $$2Other$$arepeated measurements
000167435 7001_ $$aBüchele, Gisela$$b1
000167435 7001_ $$aBrenner, Rolf Erwin$$b2
000167435 7001_ $$aGünther, Klaus-Peter$$b3
000167435 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b4$$udkfz
000167435 7001_ $$aKoenig, Wolfgang$$b5
000167435 7001_ $$00000-0002-3563-2791$$aRothenbacher, Dietrich$$b6
000167435 773__ $$0PERI:(DE-600)2701262-1$$a10.3390/biom11020230$$gVol. 11, no. 2, p. 230 -$$n2$$p230$$tBiomolecules$$v11$$x2218-273X$$y2021
000167435 909CO $$ooai:inrepo02.dkfz.de:167435$$pVDB
000167435 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000167435 9130_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000167435 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000167435 9141_ $$y2021
000167435 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBIOMOLECULES : 2018$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Blind peer review$$d2020-08-18
000167435 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2020-08-18
000167435 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2020-08-18
000167435 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000167435 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000167435 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000167435 980__ $$ajournal
000167435 980__ $$aVDB
000167435 980__ $$aI:(DE-He78)C070-20160331
000167435 980__ $$aI:(DE-He78)C120-20160331
000167435 980__ $$aI:(DE-He78)HD01-20160331
000167435 980__ $$aUNRESTRICTED